Two companies supported by HiTT get outstanding reward.

Two companies supported by HiTT get outstanding reward.

HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license.  Qbeast is a ‘Big Data’ analysis platform that allows the indexation and visualization of data in a responsive, clear and intuitive way.   On  February, Barcelona Activa has awarded the Qbeast startup for the best business project with a high technological impact, with an economic contribution of 5.000€, in the framework of the fifth edition of the Preacceleració Program. Qbeast has also obtained an office space in the MediaTIC Incubator. HiTT has pleased worked all along with Qbeast to define its business model and its development path.  Also in February Hospital Vall d’Hebron has published that Hospital Vall d’Hebron has obtained more than € 1M benefit from the licence of a new treatment for a rare disease, representing the highest economic benefit generated by a state research institute by a patent licence. Doctors Ramon Martí (VHIR) and Michio Hirano (Columbia University) discovered the treatment in 2013. Afterwards, they licenced the patent to Modis Therapeutics, an American company, to develop the therapy. HiTT participated in the evidence review to complete the evidence package of the value dossier of the drug.   These two successful stories reinforce the idea of Barcelona as a strong life sciences and health HUB articulated around powerful core formed by public hospitals, pharmaceutical companies and research centres with which HiTT has strong and long-standing relationships.  HiTT is an international market access consultancy with a payer perspective, with offices in Barcelona born in 2013. HiTT focuses its main activity on advising and accompanying institutions, research centres and private companies in the health sector, who wish to develop and implement innovative projects to add value to the health...
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs

Oriol Sola Morales is the co-author of an article about reimbursement decisions on new oncology drugs. You can access to the entire article in this link. Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug’s risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. The article explains the authors perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisation. KEYWORDS: Oncology, patient access, HTA, reimbursement, surrogate endpoint, Health Related Quality of Life...
Big Data analytical tools project

Big Data analytical tools project

Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures. In order to know which are the needs and the characteristics of the companies that use Big Data analytical tools, HiTT is developing this study through interviews to professionals of different sectors and also, through on-line questionnaires that people that is interested in this topic can answer. We would like to gather as much information as possible to ensure that our analysis reflects the real concerns of the market. HiTT invites the professionals that use big data tools in its analytical procedure, to open this link and answer the questionnaire. Your responses will be kept anonymous. Many thanks in...
New acquisition cost of Repatha

New acquisition cost of Repatha

Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US. This is an excellent message for millions of users who preferred risk to co-pay. It is indeed a significant change, not only for the potential change it is making on access to the drug and the harm to its direct competitor, but also it sends a very powerful message to the community: the drug was overpriced by at least 60%. How do we take it from there? Do we just have to wait 1-2 years to make innovation available so that it reaches the appropriate price? The move is giving payers a strong incentive to keep asking for discounts and only build mistrust on...